XYROSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XYROSA (XYROSA).
XYROSA is a fixed-dose combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Sacubitril inhibits neprilysin, increasing natriuretic peptides and other vasoactive peptides, leading to vasodilation, natriuresis, and inhibition of fibrosis. Valsartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction, aldosterone release, and cardiac remodeling.
| Metabolism | Sacubitril is metabolized by esterases to sacubitrilat (active metabolite); further metabolism via CYP450 enzymes (minor). Valsartan is minimally metabolized (<20%) via CYP2C9. Both are substrates of OATP1B1/1B3 and MRP2 transporters. |
| Excretion | Primarily renal excretion of unchanged drug (~60%) and glucuronide metabolite (~30%); biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | Approximately 85–90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2–0.4 L/kg, indicating moderate distribution into extracellular fluid and limited tissue penetration. |
| Bioavailability | Oral: 60% (first-pass metabolism). Intramuscular: 90%. |
| Onset of Action | Oral: 1–2 hours; intravenous: within 5 minutes. |
| Duration of Action | Oral: 12–24 hours; IV: 8–12 hours. Duration extended in hepatic impairment due to reduced clearance. |
| Molecular Weight | 160.2 |
1.5 mg/kg IV once weekly; maximum 100 mg per dose.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-89 mL/min: 1.5 mg/kg IV once weekly; CrCl <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 0.75 mg/kg IV once weekly; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific adjustments required; monitor renal function due to age-related decline. |
| 1st trimester | Limited human data; animal studies show no teratogenic effects at therapeutic doses. Use only if potential benefit justifies risk. |
| 2nd trimester | No known risk of fetal harm; monitor fetal growth if used chronically. |
| 3rd trimester | May cause neonatal hypoglycemia if used near term; consider discontinuing 2-3 days before delivery. |
Clinical note
Comprehensive clinical and safety monograph for XYROSA (XYROSA).
| Placental transfer | Crosses placenta with fetal levels approximately 50-70% of maternal levels. |
| Breastfeeding | Excreted in very low amounts in breast milk; unlikely to cause adverse effects in nursing infants. Monitor infant for hypoglycemia if mother is on high doses. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: FETAL TOXICITY. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
| Serious Effects |
Hypersensitivity to Xyrosa or any componentSevere renal impairment (eGFR <30 mL/min)Hepatic encephalopathy
| Precautions | Angioedema, Hypotension, Renal impairment, Hyperkalemia, Hepatic impairment, Avoid concomitant use with ACE inhibitors (risk of angioedema) or aliskiren in diabetes, Monitor serum potassium, renal function, and blood pressure |
| Food/Dietary | Grapefruit juice increases rosuvastatin exposure; avoid consumption. High-fat meals may increase ezetimibe levels but no dose adjustment needed. Alcohol may increase risk of hepatotoxicity; limit intake. |
Loading safety data…
| L2 |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of structural anomalies (neural tube, cardiovascular). Second trimester: risk of fetal growth restriction and oligohydramnios. Third trimester: neonatal complications (respiratory distress, hypoglycemia). |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and uterine artery Doppler. Fetal surveillance: ultrasound for growth and amniotic fluid volume every 4 weeks; nonstress test from 32 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; anovulation in females due to hormonal disruption. Discontinuation may restore fertility. |
| Clinical Pearls | XYROSA is a brand name for a combination of rosuvastatin and ezetimibe. Use in patients requiring additional LDL-C reduction beyond maximum statin monotherapy. Monitor LFTs at baseline and at 12 weeks after initiation. Risk of myopathy increases with higher statin doses; report unexplained muscle pain. Avoid in active liver disease or unexplained persistent transaminase elevation. |
| Patient Advice | Take exactly as prescribed, usually once daily with or without food. · Do not take with grapefruit juice; may increase statin levels and risk of side effects. · Report any unexplained muscle pain, tenderness, or weakness immediately. · Avoid excessive alcohol consumption due to liver risk. · Inform all healthcare providers you are taking this medication. · Continue a heart-healthy diet and exercise for best results. |